Journal of the neurological sciences · 2026
No interferon-beta antibodies in natalizumab-treated multiple sclerosis patients with progressive multifocal leukoencephalopathy.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gelissen Liza M Y, Wijburg Martijn T, Strijbis Eva M M, de Jong Brigit A, van Oosten Bob W, Deisenhammer Florian, van Kempen Zoé L E, Killestein Joep
Аннотация
BACKGROUND: Interferon beta therapy (IFN-β) can induce production of antibodies (NAbs) that may neutralize both therapeutic IFN-β and endogenous IFN-β, potentially impairing antiviral immunity.
OBJECTIVES: To investigate whether NAbs against IFN-β occur in multiple sclerosis patients that developed natalizumab-associated progressive multifocal leukoencephalopathy (NTZ-PML).
METHODS: Seven NTZ-PML patients were matched with natalizumab-treated patients with prior IFN-β exposure. All were tested for NAbs against IFN-β in serum.
RESULTS: NAbs against IFN-β were absent in all NTZ-PML cases, but present in three matched patients.
CONCLUSIONS: These findings do not suggest a contributing role for IFN-β NAbs in natalizumab-associated PML.
OBJECTIVES: To investigate whether NAbs against IFN-β occur in multiple sclerosis patients that developed natalizumab-associated progressive multifocal leukoencephalopathy (NTZ-PML).
METHODS: Seven NTZ-PML patients were matched with natalizumab-treated patients with prior IFN-β exposure. All were tested for NAbs against IFN-β in serum.
RESULTS: NAbs against IFN-β were absent in all NTZ-PML cases, but present in three matched patients.
CONCLUSIONS: These findings do not suggest a contributing role for IFN-β NAbs in natalizumab-associated PML.